Most Read Articles
24 Sep 2019
Obese patients are exposed to greater doses of radiation during radiofrequency ablation for atrial fibrillation, a recent study has found.
01 Oct 2019
Patients with greater ischaemia who underwent positron emission tomography (PET) myocardial perfusion imaging (MPI) have better survival with early revascularization, reports a study. Exploratory analyses reveal a lower threshold than that previously reported for single-photon emission computed tomography (SPECT).
Audrey Abella, 07 Oct 2019
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final r­esults of the EXCEL* trial presented at TCT 2019.

High HDL cholesterol levels cardioprotective in tofacitinib-treated RA patients

10 May 2019

Increases in levels of high-density lipoprotein (HDL-C) but not low-density lipoprotein (LDL-C) or total cholesterol (TC) after 24 weeks of tofacitinib treatment translate to a lower risk of future major adverse cardiovascular events (MACEs), according to a study.

Researchers conducted a posthoc analysis of six phase III trials and two long‐term extension studies over 7 years involving patients with moderately to severely active RA receiving ≥1 tofacitinib dose. Cox regression models were used to evaluate associations between baseline variables and time to first MACE following 24 weeks of tofacitinib initiation.

A total of 52 MACEs occurred over 12,873 patient‐years of exposure, with an incidence rate of 0.4 patient with events/100 patient‐years.

In univariable analyses of baseline variables, traditional cardiovascular risk factors, as well as use of corticosteroid and statin, emerged as risk factors for MACE risk in RA. No such associations were obtained for disease activity and inflammation measures.

In subsequent multivariable analyses, baseline age, hypertension and TC/HDL‐C remained significantly associated with the risk of MACE. Conversely, HDL‐C increases and TC/HDL‐C decreases after 24 weeks of tofacitinib treatment conferred a protective benefit. Changes in TC, LDL‐C and disease activity measures had no effect on MACE risk.

Finally, erythrocyte sedimentation rate increases trended with increased future MACE risk.

Researchers stressed the need for more data to further evaluate the cardiovascular safety of tofacitinib for RA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
24 Sep 2019
Obese patients are exposed to greater doses of radiation during radiofrequency ablation for atrial fibrillation, a recent study has found.
01 Oct 2019
Patients with greater ischaemia who underwent positron emission tomography (PET) myocardial perfusion imaging (MPI) have better survival with early revascularization, reports a study. Exploratory analyses reveal a lower threshold than that previously reported for single-photon emission computed tomography (SPECT).
Audrey Abella, 07 Oct 2019
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final r­esults of the EXCEL* trial presented at TCT 2019.